Bullish options flow was detected in BMY stock for a second day.

Bullish options flow detected in BMY stock for a second day. Screenshot above is the options flow on November 27, 2019.

Click here to download BMY’s options flow on November 27, 2019.

On November 27, 2019, Gabelli analyst Kevin Kedra initiated coverage of Bristol-Myers Squibb CVR (BMY-R) with a Buy rating and private market value estimate of $3.50. CVR holders will receive a $9.00 payout if all three of the FDA approval milestones are met, Kedra tells investors in a research note. The analyst sees an 80% probability for the ozanimod milestone, an 86% probability for JCAR017, and 68% probability for bb2121. He recommends the Bristol-Myers CVR as an attractive risk/reward opportunity with multiple near-term catalysts.

On November 25, 2019, in an interview on CNBC’s Mad Money, Bristol-Myers (BMY) CEO Giovanni Caforio said: We have a great pipeline and great people… We are positioned to succeed… Our position in cell therapy is one of the great programs we have right now… We recently announced a partnership with Fitbit (FIT)… We think we can grow through technology… The next frontier for growth is the early stage of cancer… We take a responsible approach to drug pricing, but we see a need for change in the system…Renewing our portfolio was really the rationale for acquiring Celgene (CELG).

finviz dynamic chart for  BMY
Bristol-Myers News From Google